C. Diff clinical trials at University of California Health

4 in progress, 1 open to eligible people

Showing trials for

  • VE303 for Prevention of Recurrent Clostridioides Difficile Infection

    open to eligible people ages 12 years and up

    The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in participants who receive a 14-day course of VE303 or matching placebo. The objectives and endpoints are identical for Stage 1 (recurrent CDI) and Stage 2 (high-risk primary CDI).

    at UCLA

  • CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection

    “Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”

    Sorry, in progress, not accepting new patients

    The purpose of this research is to evaluate the primary objectives of safety and efficacy (rate of clinical cure) of 2 dosages of CRS3123 (200 mg and 400 mg) administered orally (po) twice daily (bid) and vancomycin administered 125 mg PO 4 times daily (qid) in adults > or equal to 18 years of age with a primary episode or first recurrence of CDI. The study will investigate the plasma concentrations and HRQoL outcomes of CRS3123 and additional efficacy endpoints as secondary objectives.

    at UC Irvine

  • Optimal Treatment for Recurrent Clostridium Difficile

    Sorry, in progress, not accepting new patients

    The purpose of this study is to determine whether fidaxomicin and vancomycin followed by taper and pulse vancomycin treatment are superior to standard vancomycin treatment for the treatment of recurrent Clostridium difficile infection.

    at UCSD

  • Fecal Microbiota Transplant National Registry

    Sorry, not currently recruiting here

    A national data registry of patients receiving fecal microbiota transplantation (FMT) or other gut-related-microbiota products designed to prospectively assess short and long-term safety and effectiveness

    at UCLA UCSD UCSF

Our lead scientists for C. Diff research studies include .

Last updated: